Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexapro

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

- PMLiVE

Pharma investment in marketing flat in 2013

And top 10 companies reduced yearly spend on sales force and marketing channels

EU flag

EFPIA: pharma must play key role in healthcare reform

Trade body publishes strategy to put industry at heart of economic growth

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

- PMLiVE

AZ circles wagons as Pfizer hints at hostile takeover

Aims for annual revenues of $45bn by 2023

- PMLiVE

Sex is a good trick

But pharma companies - and payers - should stop incestuous ‘best practice’ behaviours and look for new ways of comparing options

- PMLiVE

Abilify Maintena launches in Europe

Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

Novartis building

New York plant set to close as Novartis continues cutbacks

More than 500 employees face the axe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links